Pdl Biopharma, Inc.

Abbvie Inc.

Progenics Pharmaceuticals, Inc.

Facet Biotech Corporation

Abbott Laboratories Corporation

Abbvie Biotherapeutics Inc.

Eli Lilly and Company

Genetics Institute, Inc.

Arius Research, Inc.

Abbott Biotherapeutics Corp.

Abbvie Bahamas Limited

Paul Robert Hinton

Naoya Tsurushita

Shankar Kumar

Richard W Dixon

Jonathan P Belk

Maximiliano Vasquez

Yan Chen

Chengbin Wu

Maria A Argiriadi

Hua Ying

Carolyn A Cuff

Terry L Melim

William C Olson

J Yun Tso

Paul J Maddon

Michael Roguska

Emma Fung

Susan E Lacy

Maximillano Vasquez

David S F Young

Susan E Hahn

Clive R Wood

Mary Collins

Gary S Gray

Helen P Findlay

Fiona A Harding

Nicholas F Landolfi

Veronica Juan

Katherine Jane Turner

Beatriz M Carreno

Denise M O'Hara

Daad Sayegh

Shiming Ye

Luis A G Da Cruz

Olivia Jennifer Razo

Kristian Rogers

Donna Morris

Mengli Xiong

Yun J Tso

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Interleukin-13 binding proteins

The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.

Fc variants with improved complement activation

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

IL-12/p40 binding proteins

The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.

Alteration of Fc-fusion protein serum half-lives by mutagenesis

The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.

Anti-CCR5 antibody

The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

Cytotoxicity mediation of cells evidencing surface expression of CD63

The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.

Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Growing community of inventors

Sunnyvale, CA, United States of America

Paul Robert Hinton